Other studies have shown that patients with hypergammaglobulinemia and hypocomplementemia have a higher rate of developing lymphomas, so continued monitoring of these serologic markers after diagnosis of SS is also important. “In the future, hopefully new biomarkers will be identified that will facilitate and accelerate the diagnosis of SS, and future classification will likely rely on such biomarkers,” says Dr. Shiboski.
Susan Bernstein is a freelance medical journalist based in Atlanta.
ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
References
- Shiboski CH, Baer AN, Shiboski SC, et al. Natural history and predictors of progression to Sjögren’s syndrome among participants of the Sjögren’s International Collaborative Clinical Alliance Registry. Arthritis Care Res (Hoboken). 2018 Feb;70(2):284–294.
- Maciel G, Crowson CS, Matteson EL, et al. Prevalence of primary Sjögren’s syndrome in a U.S. population-based cohort. Arthritis Care Res (Hoboken). 2017 Oct;69(10):1612–1616.
- Jonsson R, Bolstad AI, Brokstad KA, et al. Sjögren’s syndrome—a plethora of clinical and immunological phenotypes with a complex genetic background. Ann NY Acad Sci. 2007 Jun;1108:433–447.
- Shiboski SC, Shiboski CH, Criswell L, et al. American College of Rheumatology classification criteria for Sjögren’s syndrome: A data-driven, expert consensus approach in the Sjögren’s International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken). 2012 Apr;64(4):475–487.
- Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren’s syndrome: A consensus and data-driven methodology involving three international cohorts. Arthritis Rheumatol. 2017 Jan;69(1):35–45.
- Cartee DL, Maker S, Dalonges D, et al. Sjögren’s syndrome: Oral manifestations and treatment, a dental perspective. J Dent Hyg. 2015 Dec;89(6):365–371.
